Fauzia Riaz

Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01

Aditya Bardia, Komal Jhaveri, Seock‐Ah Im et al. · Journal of Clinical Oncology · 2024 · 140 citations · Full text

Medicine, Oncology, Pharmacology +17

NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022

Elizabeth A. Griffiths, Vivek Roy, Laura Alwan et al. · Journal of the National Comprehensive Cancer Network · 2022 · 76 citations · Full text

Medicine, Hematology, Oncology +16

Uptake and Survival Outcomes Following Immune Checkpoint Inhibitor Therapy Among Trial-Ineligible Patients With Advanced Solid Cancers

Ravi B. Parikh, Eun Jeong Min, E. Paul Wileyto et al. · JAMA Oncology · 2021 · 62 citations · Full text

Medicine, Immunology, Oncology +17

Trends in Checkpoint Inhibitor Therapy for Advanced Urothelial Cell Carcinoma at the End of Life: Insights from Real-World Practice

Ravi B. Parikh, Matthew D. Galsky, Bishal Gyawali et al. · The Oncologist · 2019 · 44 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Adoption of Immune Checkpoint Inhibitors and Patterns of Care at the End of Life

Fauzia Riaz, Geliang Gan, Fangyong Li et al. · JCO Oncology Practice · 2020 · 34 citations · Full text

Medicine, Oncology, Pharmacoeconomics +17